CA3136633A1 - Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders - Google Patents

Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders Download PDF

Info

Publication number
CA3136633A1
CA3136633A1 CA3136633A CA3136633A CA3136633A1 CA 3136633 A1 CA3136633 A1 CA 3136633A1 CA 3136633 A CA3136633 A CA 3136633A CA 3136633 A CA3136633 A CA 3136633A CA 3136633 A1 CA3136633 A1 CA 3136633A1
Authority
CA
Canada
Prior art keywords
memantine
azelastine
pharmaceutical composition
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3136633A
Other languages
English (en)
French (fr)
Inventor
Jianmin Wang
Geping Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LA Pharmatech Inc
Original Assignee
LA Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LA Pharmatech Inc filed Critical LA Pharmatech Inc
Publication of CA3136633A1 publication Critical patent/CA3136633A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3136633A 2019-04-12 2019-04-12 Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders Pending CA3136633A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/027293 WO2020209872A1 (en) 2019-04-12 2019-04-12 Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

Publications (1)

Publication Number Publication Date
CA3136633A1 true CA3136633A1 (en) 2020-10-15

Family

ID=72751206

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3136633A Pending CA3136633A1 (en) 2019-04-12 2019-04-12 Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

Country Status (6)

Country Link
EP (1) EP3952840A4 (ja)
JP (1) JP7365426B2 (ja)
CN (1) CN113939276A (ja)
AU (1) AU2019445048A1 (ja)
CA (1) CA3136633A1 (ja)
WO (1) WO2020209872A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
WO2020222799A1 (en) * 2019-04-30 2020-11-05 La Pharma Tech Inc. A method of treating mental, behavioral, cognitive disorders
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704482T3 (es) * 2004-11-24 2019-03-18 Meda Pharmaceuticals Inc Composiciones que comprenden azelastina y sus métodos de uso
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2018081508A1 (en) * 2016-10-28 2018-05-03 Chase Pharmaceutical Corporation Memantine combinations and use
JP7198575B2 (ja) * 2017-07-11 2023-01-04 キョーリンリメディオ株式会社 メマンチン塩酸塩含有口腔内崩壊錠

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Also Published As

Publication number Publication date
EP3952840A4 (en) 2022-11-23
JP7365426B2 (ja) 2023-10-19
EP3952840A1 (en) 2022-02-16
JP2022535644A (ja) 2022-08-10
AU2019445048A1 (en) 2021-12-02
CN113939276A (zh) 2022-01-14
WO2020209872A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
US10946026B2 (en) Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
JP7365426B2 (ja) 精神障害、行動障害、認知障害を処置するための医薬組成物及び方法
US11116773B2 (en) Method of treating dementia
US10639315B1 (en) Pharmaceutical compositions and methods for treating Alzheimer's disease
US11389458B2 (en) Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US10898493B2 (en) Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11690849B2 (en) Method of treating dementia
WO2020222799A1 (en) A method of treating mental, behavioral, cognitive disorders
CN114072945A (zh) 用于治疗精神障碍、行为障碍、认知障碍的新型药物组合物和方法
ES2952727T3 (es) Tratamiento de la enfermedad de Alzheimer en una población de pacientes particular
KR20080068766A (ko) 흥분 및 그 밖의 다른 행동 장애, 특히 알츠하이머 질환과연관된 것을 치료하기 위한 1-아미노사이클로헥산 유도체
US20210069209A1 (en) Novel pharmaceutical compositions and methods for menopause related anxiety and depression
JP2023058666A (ja) アルツハイマー型認知症予防または治療剤
JP6084931B2 (ja) ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
CN114901282B (zh) 在痴呆患者中治疗行为和精神症状
US20130072474A1 (en) Treatment of dementia of alzheimer's type with masitinib
Porsteinsson et al. Memantine in the treatment of Alzheimer’s disease